News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AWM Investment Company Inc. has made a new $9.81 million investment in SOPHiA GENETICS SA, purchasing 1,700,000 shares. This makes AWM Investment Company Inc. a 2.03% stakeholder in the company. Other institutional investors have also recently modified their holdings in SOPHiA GENETICS, and several โฆ
An officer at SOPHiA GENETICS (NASDAQ: SOPH), Zhenyu Xu, intends to sell an additional 8,000 shares of common stock under Rule 144, valued at $60,960. These shares are founder shares acquired in 2012 and are held at Morgan Stanley Smith Barney LLC Executive Financial โฆ
This article provides financial information for SOPHiA GENETICS SA (DUS:90B) on the Dusseldorf Stock Exchange, specifically focusing on its EBIT per share. It appears to be a data-driven page, showing periods, values, and percentage changes related to the company's EBIT per share, along with โฆ
SOPHiA GENETICS SA (NASDAQ:SOPH) has received a consensus "Hold" rating from five analysts, with an average 12-month price target of $10.00 against a current price of $7.50. The company recently surpassed revenue expectations but reported a wider-than-anticipated adjusted loss per share. Insider selling and โฆ
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company's stock on August 13th for $30,080, reducing his position by 0.68%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and Xu has made several other sales since early July. โฆ
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company's stock on August 13th for $30,080, reducing his position by 0.68%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and Xu has made several other sales since early July. โฆ
Sei Investments Co. has acquired 357,888 shares of SOPHiA GENETICS SA (NASDAQ:SOPH) for approximately $1.77 million, giving it a 0.52% stake in the company. Despite this institutional investment, SOPHiA GENETICS remains unprofitable, reporting a quarterly loss of $0.26 per share, worse than estimates, although โฆ
SOPHiA GENETICS (SOPH) has filed a Form 144 indicating a proposed sale of 20,000 common shares with an aggregate market value of $133,800.00, anticipated on August 7, 2026. This filing also details previous Rule 10b5-1 plan sales by Jurgi Camblong, including significant transactions on โฆ
SOPHiA GENETICS CTO Abhimanyu Verma sold 5,000 shares of the company's stock for $38,000, reducing his total holdings to 182,171 shares. This sale, executed under a Rule 10b5-1 trading plan, follows several other recent insider transactions. Despite the stock trading near its 12-month high, โฆ
HC Wainwright has lowered its FY2029 earnings per share forecast for SOPHiA GENETICS (NASDAQ: SOPH) to $0.31 from $0.34, while maintaining a Buy rating and a $14 price target. The company recently reported a quarterly loss of $0.26 per share, missing consensus estimates, despite โฆ
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of the company's stock on August 4th, reducing their position by 1.64%. The transaction, valued at $69,200, was conducted under a pre-arranged Rule 10b5-1 plan. Despite the insider sale and a recent stock dip, analysts โฆ
SOPHiA GENETICS has announced a multi-year global partnership with AstraZeneca to develop and launch two companion diagnostics for precision oncology therapies. This collaboration aims to create decentralised clinical trial assays and diagnostic solutions for both solid tumors and blood cancers. The goal is to โฆ
SOPHiA GENETICS Chairman Jurgi Camblong sold 20,000 shares of the company's stock for $138,400 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 0.57%. This insider sale comes amidst mixed quarterly results where revenue exceeded expectations but the company reported a larger-than-anticipated loss โฆ
SOPHiA GENETICS SA (NASDAQ:SOPH) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.20, which beat estimates by $0.02. The company also announced revenue of $23.31M, representing a 27.22% year-over-year increase and beating expectations by $1.60M. The slide deck was released in โฆ
SOPHiA GENETICS (SOPH) has filed its Q2 2026 Form 6-K with the SEC, which includes unaudited interim financial statements and management discussion. This filing provides transparency to investors regarding the company's financial performance and operational trends. While analysts rate SOPH as a Buy with โฆ
SOPHiA GENETICS (NASDAQ:SOPH) reached a new 52-week high following an analyst upgrade from BTIG Research, which raised its price target from $8 to $9 and maintained a Buy rating. The company reported strong Q2 2026 revenue of $23.3 million, a 27% year-over-year increase, and โฆ
SOPHiA GENETICS SA has pre-announced positive earnings, with estimated FY26 revenue now ranging from $94-$96 Million, an increase from the previous estimate of $92-$94 Million. This positive revision is part of a broader trend of news surrounding the company's collaborations and financial performance. The โฆ
BTIG Research has raised its price target for SOPHiA GENETICS (NASDAQ:SOPH) to $9.00 from $8.00, maintaining a "buy" rating and suggesting a 31.58% upside. This positive outlook follows the company's Q2 2026 revenue beat, an increased full-year revenue outlook of $94 million-$96 million, and โฆ
BTIG has increased its price target for Sophia Genetics SA (NASDAQ:SOPH) to $9.00 from $8.00, maintaining a Buy rating, following the company's better-than-expected second-quarter results and two new companion diagnostics deals with AstraZeneca. Sophia Genetics reported 27% revenue growth, driven by volume increases and โฆ
SOPHiA GENETICS announced a global, multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics (CDx) for precision oncology therapies. This partnership aims to integrate SOPHiA GENETICS's decentralized clinical trial assays and CDx capabilities to support AstraZeneca's treatments, focusing on both solid tumor โฆ
Jurgi Camblong, an insider at SOPHiA GENETICS SA (SOPH), has filed a notice to sell 20,000 common shares totaling $113,800.00, with the sale expected on August 4, 2026. This filing also discloses previous Rule 10b5-1 sales, including 20,000 shares sold on July 21, 2026, โฆ
SOPHiA GENETICS insider Zhenyu Xu plans to sell 10,000 shares of common stock on NASDAQ, valued at approximately $56,900. These "Founders Shares" were acquired in 2012, and the sale is being conducted through Morgan Stanley Smith Barney LLC Executive Financial Services under a Rule โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States